Release time：Feb 17, 2022
Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of the whole industry chain, announced that the IND application of self-developed 8MW2311 for injection was accepted by the National Medical Products Administration (NMPA).
8MW2311 for injection is a polyethylene glycol coupled human interleukin-2 immunoagonist for the treatment of advanced malignant tumors. After 8MW2311 is injected into the body, it can stimulate the phosphorylation of downstream transcription factor STAT5 and effectively stimulate the proliferation of killer T lymphocyte CD8+T cells, so as to exert its efficacy. Preclinical study results showed that 8MW2311 enriched in tumor tissue and preferentially activated the pharmacological effect of CD8+T cells. It showed sustained and effective antitumor effect in a variety of tumor models, and showed significantly enhanced synergistic antitumor effect in combination with immune checkpoint drugs (such as anti-PD-1 antibody).
